



Manulife Dragon Growth Fund[†]

A flexible approach to capture opportunities in China and Hong Kong


-  Potential growth opportunities from Hong Kong and China equities
-  Leveraging consumption upgrade, innovations and policy tailwinds to spur growth
-  Flexible allocation between China and Hong Kong equities

[†] The full name of the Fund is Manulife Global Fund — Dragon Growth Fund

The case for China and Hong Kong equities

China is leading the world's GDP growth

According to IMF forecasts, China's GDP growth is expected to normalize to 4.4% in 2022, a **growth rate that still outpaces** other major economies.




Source: IMF, World Economic Outlook, as of April 2022.

Secular consumption trend: "Guo Chao"

Chinese domestic brands have gained popularity in the past decade, reshaping the competitive landscape for various consumer sectors such as cosmetics. This is due to a trend known as **Guo Chao (国潮)**, which refers to the rise of homegrown Chinese brands.

Chinese brands' share trend in cosmetics*




Source: Euromonitor, UBS, as of September 2021.

Homegrown innovation and self-sufficiency

Strengthening innovation capacity and achieving breakthroughs in core technologies are key for China's "dual circulation" strategy. We expect to see more **domestic national champions** thriving on homegrown innovation and achieving scale, such as in electric vehicle areas.

Market share of global electric vehicle battery manufacturers (2020)*




Source: GGLB, Citic Securities, as of November 2021.

Long runway for renewable energy

In order to meet its ambitious target of carbon neutrality by 2060, China is **stepping up efforts on sustainability**. The share of non-fossil fuels in primary energy consumption is expected to rise to around 20% by 2025, 25% by 2030 and over 80% by 2060, from 15.9% in 2020, according to government targets, with the solar and wind industries being major beneficiaries.

China's renewable energy annual capacity addition (in gigawatt)*



Source: Tsinghua, J.P. Morgan estimates based on Tsinghua's LT energy consumption by fuel type. FYP means China's Five-Year Plan. As of June 2021.

Why Manulife Dragon Growth Fund

Capturing growing trends: three key investment themes

Consumption upgrade



Property management services and cosmetics companies should benefit from Chinese consumers' willingness to upgrade their quality of life.

Conviction is the key in stock selection

Our investment team holds a medium- to long-term view, but makes adjustments in the short-term according to market conditions. We aim to hold a concentrated portfolio with **40-55 stocks**¹.

R&D / innovation




China's government and corporations emphasize R&D and innovation to improve competitiveness, especially in sectors like high technology, industrial applications, and healthcare.


Flexible allocation between China and Hong Kong equities

Our investment team makes flexible and dynamic allocations between China and Hong Kong equities, according to changes in market conditions, government policies and industry trends.

Policy tailwinds




The Chinese government may continue to support several key policy areas, such as import substitution for technology and healthcare.



Award-winning team

Winning a wide range of awards over the **past 7 years**²

**Morningstar Fund Awards
Hong Kong 2021**
Best Hong Kong Equity Fund



**BENCHMARK Fund of the
Year Awards 2020**
Hong Kong Equity – Best-in-Class



About Manulife Investment Management

40+

Equity investment experts
in the Greater China region

25+ years

Track record

Source: As of 30 June 2022. Note: Some professionals may support additional asset classes. Based in China, Manulife TEDA Fund Management Company Limited is a joint venture between Manulife (49%) and Northern International Trust (51%), part of the Tianjin TEDA Investment Holding Co. Ltd.

1. Manulife Investment Management, as of 30 June 2022. This is an illustrative guideline. Portfolio holdings and characteristics are subject to change at any time. Information about the asset allocation is historical and is not an indication of the future composition.

2. Manulife Investment Management (Asia), as of 30 June 2022. Awards issued by different sponsors are for reference only, and should not be construed as an endorsement of Manulife Investment Management, its affiliates or its products. Please refer to the respective websites of the sponsors of these awards for more information regarding the criteria and manner in which such awards are determined. Morningstar Awards Hong Kong 2021 are issued based on the best risk adjusted performance as of December 2020 within their Morningstar Categories or groupings of Morningstar Categories, subject to qualitative review. Morningstar Awards 2021 (c). Morningstar, Inc. All Rights Reserved. Awarded to Manulife Dragon Growth Fund AA HKD for the Best Hong Kong Equity Fund. Benchmark Fund of the Year Awards are issued based on the assessment criteria of the sponsor. Outstanding Achiever for 2014 and 2015, Retail Class – Best-in-class for 2016, House Award - Best-in-class for 2017, 2018 and 2020. This award reflects the performance of the Fund as of September of the year mentioned. Bloomberg BusinessWeek (Chinese Edition) Top Fund Awards 2015 are issued based on the assessment criteria of the sponsor and performance data of funds. This award reflects the performance of the Fund – Class A as of September of the year mentioned. Fund Selector Asia Awards 2017 are issued based on the assessment criteria of the sponsor and performance data of funds. This award reflects the performance of the Fund – Class A as of June 2016. Citywire Asia Awards are issued based on the assessment criteria of the sponsor and performance data of funds. Citywire Best Fund Manager Awards – Hong Kong Equity for 2016, 2018, 2020. reflecting the 3-year performance of the Fund as of December of the prior year (i.e. 2015, 2017, 2019). Citywire Best Fund Group Awards – Hong Kong Equity for 2017, 2018, 2019 and 2020, recognising the expertise of the group as a whole in managing money in specific investment sectors over seven years (i.e. Dec 2009 – Dec 2016, Dec 2010 – Dec 2017, Dec 2011 – Dec 2018 and Dec 2012 – Dec 2019).

Share class	AA(Accumulation)	AA (USD) MDIST (G)	AA (SGD Hedged) MDIST (G)
Investment objective	The Fund aims to achieve capital growth by investing at least 70% of its net assets in a diversified portfolio of equity and equity related securities of public companies which are listed in Hong Kong and/or, although not listed in Hong Kong, are listed on a stock exchange in any other jurisdiction and have substantial business interests in Hong Kong and/or China. Such equity and equity related securities include common stocks, preferred stocks and depositary receipts.		
Inception date	13 December 2016	14 December 2018	16 April 2020
ISIN code	LU1328277881	LU1813983027	LU2039709279
Bloomberg ticker	MADRGRA LX	MLHEAUM LX	MLHESHG LX
Base currency	USD		
Mode of subscription	Cash		
Minimum initial investment	USD 1,000 (or the equivalent in any other major currency)		
Distribution frequency	Annually	Monthly	Monthly
Management fee	1.50%		
Initial sales charge	Up to 5%		
Dealing frequency	Daily		
Investment manager	Manulife Investment Management (Hong Kong) Limited		
Fund Size	USD 427.6 million / SGD 591.9 million (as of 31 July 2022)		

*The above information may contain projections or other forward-looking statements regarding future events, targets, management discipline or other expectations. There is no assurance that such events will occur, and the future course may be significantly different from that shown here.

Important notes:

Manulife Global Fund (the "Company") is an open-ended investment company registered in the Grand Duchy of Luxembourg. The Manulife Global Fund — Dragon Growth Fund (the "Fund") is recognised under the Securities and Futures Act of Singapore for retail distribution. The Company has appointed Manulife Investment Management (Singapore) Pte. Ltd. as its Singapore Representative and agent for service of process in Singapore. The information provided herein does not constitute financial advice, an offer or recommendation with respect to the Fund.

Opinions, forecasts and estimates on the economy, financial markets or economic trends of the markets mentioned herein are not necessarily indicative of the future or likely performance of the Fund. **The Fund may use financial derivative instruments for efficient portfolio management and/or hedging.**

Investments in the Fund are not deposits in, guaranteed or insured by the manager and involve risks. Past performance of the manager or sub manager is not necessarily indicative of its future performance and any income accruing to them may fall or rise. Past performance of the Fund is not necessarily indicative of future performance. The value of units in the Fund and any income accruing to them may fall or rise. Past performance of the Fund is not necessarily indicative of future performance. Investors should read the prospectus, and seek advice from a financial adviser before deciding whether to purchase units in the Fund. A copy of the prospectus and the product highlights sheet can be obtained from Manulife or its distributors. In the event an investor chooses not to seek advice from a financial adviser, he should consider whether the Fund is suitable for him.

Distributions are not guaranteed. Investors should refer to the Singapore prospectus for the distribution policy of the Fund. The Directors of the Company shall have the absolute discretion to determine whether a distribution is to be made in respect of the Fund as well as the rate and frequency of distributions to be made. Distributions may be made out of (a) income, or (b) net capital gains, or (c) capital of the Fund, or (d) gross income while charging all or part of the fees and expenses to capital, or (e) any combination of (a), (b), (c) and/or (d). Past distribution yields and payments are not necessarily indicative of future distribution yields and payments. Any payment of distributions by the Fund is expected to result in an immediate decrease in the net asset value per share of the Fund.

This advertisement or publication has not been reviewed by the Monetary Authority of Singapore.

Information is correct as of 31 July 2022, unless otherwise stated.